An observational study to investigate the safety and efficacy of niraparib for Japanese patients with recurrent ovarian cancer: maintenance therapy for platinum-sensitive recurrent treatment and monotherapy for late-line treatment
Latest Information Update: 17 Mar 2022
At a glance
- Drugs Niraparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Acronyms JGOG3031
Most Recent Events
- 17 Mar 2022 New trial record